Akebia Therapeutics, Inc. (AKBA) News
Filter AKBA News Items
AKBA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKBA News Highlights
- For AKBA, its 30 day story count is now at 9.
- Over the past 26 days, the trend for AKBA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, LOAN and BEAT are the most mentioned tickers in articles about AKBA.
Latest AKBA News From Around the Web
Below are the latest news stories about AKEBIA THERAPEUTICS INC that investors may wish to consider to help them evaluate AKBA as an investment opportunity.
Akebia Therapeutics to Present at Piper Sandler Healthcare ConferenceAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST. |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call TranscriptAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript November 8, 2023 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.09. Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics’ Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only […] |
Q3 2023 Akebia Therapeutics Inc Earnings CallQ3 2023 Akebia Therapeutics Inc Earnings Call |
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights. |
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon AdvisorsAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has amended the terms of its loan agreement with Pharmakon Advisors, LP, the investment manager of the BioPharma Credit funds that it originally entered into in November 2019. The amendment extends the maturity date of the loan to March of 2025 from November 11, 2024. Under the terms of the amendment, Akebia's quarterly principal pay |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 61,000 shares of Akebia's common stock on October 31, 2023, as an inducement material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business HighlightsAkebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023, prior to the open of financial markets. |
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseAkebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney DiseaseAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the U.S. Food and Drug Administration (FDA) has acknowledged that the resubmission to its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis, was complete. The FDA has classified this as a class 2 response, which results in a six-month review period from |
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023. |